General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Items 201–300 of 612
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates
Sapra, P., Betts, A. M., & Boni, J. P. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.827405 · Cited by 30
Melhem, M. R., Delor, I., Ruixo, J. J. P., Harrold, J. M., Chow, A. T., Wu, L. S., & Jacqmin, P. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13504 · Cited by 29
Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
Thomas, X. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679359 · Cited by 29
Chan, L. J., Ascher, D. B., Yadav, R., Bulitta, J. B., Williams, C. C., Porter, C. J. H., Landersdorfer, C. B., & Kaminskas, L. M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00749 · Cited by 30
Djebli, N., Martinez, J.-M., Lohan, L., Khier, S., Brunet, A., Hurbin, F., & Fabre, D. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0505-1 · Cited by 30
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14684 · Cited by 29
Proctor, J. R., & Wong, H. H. (2023) · Clinical and Translational Science · doi:10.1111/cts.13676 · Cited by 29
Ait‐Oudhia, S., Straubinger, R. M., & Mager, D. E. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0775-8 · Cited by 28
Self-citationAit‐Oudhia, S., Straubinger, R. M., & Mager, D. E. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.199109 · Cited by 28
Self-citationZhang, L., & Mager, D. E. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9445-x · Cited by 28
Self-citationTang, C., & Prueksaritanont, T. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0471-0 · Cited by 27
Zdovc, J. A., Hanžel, J., Kurent, T., Sever, N., Koželj, M., Smrekar, N., Novak, G., Štabuc, B., Dreesen, E., Thomas, D., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101587 · Cited by 27
Liu, D., Lon, H., Wang, Y., DuBois, D. C., Almon, R. R., & Jusko, W. J. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1838 · Cited by 27
Self-citationHow Transporters Have Changed Basic Pharmacokinetic Understanding
Benet, L. Z., Bowman, C. M., & Sodhi, J. K. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0373-3 · Cited by 28
Marathe, A., Krzyżański, W., & Mager, D. E. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9118-8 · Cited by 27
Self-citationChudasama, V. L., Zutshi, A., Singh, P., Abraham, A. K., Mager, D. E., & Harrold, J. M. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9401-1 · Cited by 27
Self-citationLuu, K. T., Kraynov, E. A., Kuang, B., Vicini, P., & Zhong, W.-Z. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9464-8 · Cited by 26
Predicting the Onset of Nonlinear Pharmacokinetics
Stein, A. M., & Peletier, L. A. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12316 · Cited by 27
Wiczling, P., Lowe, P. J., Pigeolet, E., Lüdicke, F., Balser, S., & Krzyżański, W. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318090-000000000-00000 · Cited by 26
Multi-scale modeling of drug binding kinetics to predict drug efficacy
Clarelli, F., Liang, J., Martinecz, A., Heiland, I., & Wiesch, P. A. Z. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03376-y · Cited by 25
Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties
Gabrielsson, J., & Peletier, L. A. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0031-y · Cited by 25
Topics in Mathematical Pharmacology
van der Graaf, P. H., Benson, N., & Peletier, L. A. (2015) · Journal of Dynamics and Differential Equations · doi:10.1007/s10884-015-9468-4 · Cited by 25
Deng, R., & Balthasar, J. P. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20828 · Cited by 25
Endres, C. J., Salinger, D. H., Köck, K., Gastonguay, M. R., Martin, D. A., Klekotka, P. A., Nirula, A., & Gibbs, M. A. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.334 · Cited by 26
Yamazaki, S., Shen, Z., Jiang, Y., Smith, B. J., & Vicini, P. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.051490 · Cited by 24
Li, Y., Vaughan, K. L., Tweedie, D., Jung, Y. J., Kim, H. K., Choi, H.-I., Kim, D. S., Mattison, J. A., & Greig, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53356-2 · Cited by 24
Betts, A. M., Clark, T. H., Jasper, P., Tolsma, J., van der Graaf, P. H., Graziani, E. I., Rosfjord, E. C., Sung, M. S., Ma, D., & Barletta, F. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09702-3 · Cited by 24
Glatt, D. M., Beckford-Vera, D., Parrott, M. C., Luft, J. C., Benhabbour, S. R., & Mumper, R. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00063 · Cited by 23
Mo, G., Baldwin, J. R., Luffer, D. R., Ilaria, R. L., Conti, I., Heathman, M. A., & Cronier, D. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0562-0 · Cited by 23
Bonifacio, L., Dodds, M., Prohaska, D., Moss, A. M., Giaccia, A. J., Tabibiazar, R., & McIntyre, G. (2019) · Clinical and Translational Science · doi:10.1111/cts.12706 · Cited by 23
Patsatzis, D. G., Maris, D. T., & Goussis, D. A. (2016) · Bulletin of Mathematical Biology · doi:10.1007/s11538-016-0176-y · Cited by 23
Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies
Wiesch, P. A. Z., Clarelli, F., & Cohen, T. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005321 · Cited by 27
Pasquiers, B., Benamara, S., Felices, M., Nguyen, L., & Declèves, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112754 · Cited by 23
Zheng, S., Gaitonde, P., Andrew, M., Gibbs, M. A., Lesko, L. J., & Schmidt, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.38 · Cited by 22
Learning methods for structural damage detection via entropy‐based sensors selection
Smarra, F., Tjen, J., & D’Innocenzo, A. (2022) · International Journal of Robust and Nonlinear Control · doi:10.1002/rnc.6124 · Cited by 22
Ait‐Oudhia, S., Scherrmann, J., & Krzyżański, W. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167304 · Cited by 25
Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors
Guo, Y., Remaily, B., Thomas, J. W., Kim, K., Kulp, S. K., Mace, T. A., Ganesan, L. P., Owen, D. H., Coss, C. C., & Phelps, M. A. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1683 · Cited by 22
Thai, H., Veyrat‐Follet, C., Vivier, N., Dubruc, C., Sanderink, G., Mentré, F., & Comets, E. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04015.x · Cited by 21
Li, R., Niosi, M., Johnson, N., Tess, D. A., Kimoto, E., Lin, J., Yang, X., Riccardi, K. A., Ryu, S., El‐Kattan, A. F., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078790 · Cited by 22
Sugimoto, H., Wei, D., Dong, L., Ghosh, D., Chen, S. E., & Qian, M. G. (2018) · Bioanalysis · doi:10.4155/bio-2018-0205 · Cited by 21
gQSPSim: A SimBiology‐Based GUI for Standardized QSP Model Development and Application
Hosseini, I., Feigelman, J. S., Gajjala, A., Susilo, M. E., Ramakrishnan, V., Ramanujan, S., & Gadkar, K. G. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12494 · Cited by 24
Small‐molecule compounds exhibiting target‐mediated drug disposition — A case example of ABT‐384
An, G., Liu, W., & Dutta, S. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.531 · Cited by 21
Vyver, A. J. V. D., Walz, A., Heins, M., Abdolzade‐Bavil, A., Kraft, T. E., Waldhauer, I., & Otteneder, M. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958543 · Cited by 20
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
Pétricoul, O., Nazarian, A., Schuehly, U., Schramm, U., David, O. J., Laurent, D., Præstgaard, J., Roubenoff, R., Papanicolaou, D. A., & Rooks, D. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01189-0 · Cited by 20
Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents
Doshi, S., Krzyżański, W., Yue, S. V., Elliott, S. G., Chow, A. T., & Ruixo, J. J. P. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0098-x · Cited by 22
Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies
Samineni, D., Girish, S., & Li, C. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1243055 · Cited by 21
Vlot, A. H. C., de Witte, W. E. A., Danhof, M., van der Graaf, P. H., van Westen, G. J. P., & de Lange, E. C. M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0172-7 · Cited by 21
Warnders, F.-J., Hooge, M. N. L., de Vries, E. G. E., & Kosterink, J. G. W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21498 · Cited by 20
Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
Berends, S. E., van Steeg, T. J., Ahsman, M. J., Singh, S., Brandse, J. F., D’Haens, G., & Mathôt, R. A. A. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09652-5 · Cited by 20
Stepensky, D. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599970-000000000-00000 · Cited by 20
Smart, K. A., Bröske, A.-M. E., Rüttinger, D., Mueller, C., Phipps, A., Walz, A., Ries, C. H., Baehner, M., Cannarile, M. A., & Meneses‐Lorente, G. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1964 · Cited by 20
Jonsson, E. N., Macintyre, F., James, I., Krams, M., & Marshall, S. F. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-5264-x · Cited by 20
Slow Invariant Manifolds of Singularly Perturbed Systems via Physics-Informed Machine Learning
Patsatzis, D. G., Fabiani, G., Russo, L., & Siettos, C. I. (2024) · SIAM Journal on Scientific Computing · doi:10.1137/23m1602991 · Cited by 24
Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc
Richter, F., Seifert, O., Herrmann, A., Pfizenmaier, K., & Kontermann, R. E. (2019) · mAbs · doi:10.1080/19420862.2019.1596512 · Cited by 19
Jusko, W. J., Molins, E. A. G., & Ayyar, V. S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000118 · Cited by 19
Self-citationTarget‐Mediated Drug Disposition—A Class Effect of Soluble Epoxide Hydrolase Inhibitors
An, G., Lee, K. S. S., Yang, J., & Hammock, B. D. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1763 · Cited by 19
Koyama, S., Toshimoto, K., Lee, W., Aoki, Y., & Sugiyama, Y. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000023 · Cited by 19
Urva, S., & Balthasar, J. P. (2010) · mAbs · doi:10.4161/mabs.2.1.10781 · Cited by 19
Abraham, A. K., Kagan, L., Kumar, S., & Mager, D. E. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167650 · Cited by 19
Self-citationSpilker, M. E., Singh, P., & Vicini, P. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21318 · Cited by 20
Hong, Y., Dingemanse, J., & Mager, D. E. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100495 · Cited by 25
Self-citationPharmacokinetic and Pharmacodynamic Modeling of Antibody-Drug Conjugates
Glassman, P. M. (2025) · Cancers · doi:10.3390/cancers18010005 · Cited by 18
Cheng, S., Flora, D. R., Rettie, A. E., Brundage, R. C., & Tracy, T. S. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000876 · Cited by 18
Ren, T., Zhu, X., Jusko, N. M., Krzyżański, W., & Jusko, W. J. (2022) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-022-09822-y · Cited by 18
Self-citationHansen, L., Petersen, L. C., Lauritzen, B., Clausen, J. T., Grell, S. N., Agersø, H., Sørensen, B. B., Hilden, I., & Almholt, K. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.12.015 · Cited by 18
Li, H., Köck, K., Wisler, J. A., Rees, W. A., Prince, P. J., Reynhardt, K. O., Hsu, H., Yu, Z., Borie, D. C., Salinger, D. H., et al. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.98 · Cited by 18
Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
Timmermann, S., & Hall, A. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13202 · Cited by 18
Guan, X., & Morris, M. E. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2735-z · Cited by 18
Pediatric Dose Selection for Therapeutic Proteins
Malik, P. R. V., Temrikar, Z. H., Chelle, P., Edginton, A. N., & Meibohm, B. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1829 · Cited by 18
Wright, D. H., Stone, J. A., Crumley, T. M., Wenning, L. A., Zheng, W., Yan, K. X., Yang, A. Y., Sun, L. Z., Cilissen, C., Ramael, S., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12131 · Cited by 18
Vugmeyster, Y., Tian, X., Szklut, P., Kasaian, M. T., & Xu, X. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9739-4 · Cited by 18
Impact of mathematical pharmacology on practice and theory: four case studies
Peletier, L. A., & Gabrielsson, J. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9539-8 · Cited by 18
Bach, T., Jiang, Y., Zhang, X., & An, G. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1335 · Cited by 18
Lefèvre, P. L. C., Shackelton, L. M., & Casteele, N. V. (2019) · BioDrugs · doi:10.1007/s40259-019-00366-1 · Cited by 20
Vexler, V. S., Yu, L., Pamulapati, C. R., Garrido, R., Grimm, H. P., Sriraman, P., Bohini, S., Schräml, M., Singh, U., Brandt, M., et al. (2013) · mAbs · doi:10.4161/mabs.25642 · Cited by 19
Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics
Dong, S., Nessler, I., Kopp, A., Rubahamya, B., & Thurber, G. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.836925 · Cited by 17
Quantitative structure–pharmacokinetic relationships
Xu, C., & Mager, D. E. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.537257 · Cited by 19
Self-citationBall, K., Bruin, G. J. M., Escandón, E., Funk, C., Pereira, J. N. S., Yang, T., & Yu, H. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000463 · Cited by 18
Yang, B., Doshi, S., Arkam, K., Franklin, J. L., & Chow, A. T. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0382-7 · Cited by 17
Al-Huniti, N. H., Widness, J. A., Schmidt, R. L., & Veng‐Pedersen, P. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.066027 · Cited by 17
Bussing, D., Li, Z., Li, Y., Chang, H.-P., Chang, H.-Y., Guo, L., Verma, A., & Shah, D. K. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00647-0 · Cited by 16
Wu, N., Katz, D. A., & An, G. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1925 · Cited by 17
Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies
Hu, L., & Hansen, R. J. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23504 · Cited by 17
Glassman, P. M., & Balthasar, J. P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.03.066 · Cited by 16
Ait‐Oudhia, S., Ovacik, M., & Mager, D. E. (2016) · mAbs · doi:10.1080/19420862.2016.1238995 · Cited by 17
Self-citationGlassman, P. M., & Balthasar, J. P. (2016) · mAbs · doi:10.1080/19420862.2016.1261775 · Cited by 16
Koch, G., Jusko, W. J., & Schropp, J. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9501-1 · Cited by 16
Self-citationKoch, G., Jusko, W. J., & Schropp, J. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9502-0 · Cited by 16
Self-citationModeling to capture bystander-killing effect by released payload in target positive tumor cells
Byun, J. H., & Jung, I. H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5336-7 · Cited by 16
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development
Liao, M. Z., Leipold, D. D., Chen, S., Li, Z., Kamath, A. V., & Li, C. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2351044 · Cited by 15
Desai, D. A., Schmidt, S., & Cristofoletti, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1454785 · Cited by 17
Bräm, D. S., Steiert, B., Pfister, M., Steffens, B., & Koch, G. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13265 · Cited by 19
Li, T. R., Gibiansky, L. V., Parikh, A., van der Linden, M., Sanghavi, K., Putnins, M., Sacchi, M., Feng, H., Ahmadi, T., Gupta, M., et al. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01464-2 · Cited by 15
Population Pharmacodynamic Modeling of Exenatide After 2-Week Treatment in STZ/NA Diabetic Rats
Chen, T., Kagan, L., & Mager, D. E. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23682 · Cited by 16
Self-citationA4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation
Germani, M., Bene, F. D., Rocchetti, M., & van der Graaf, P. H. (2012) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2012.10.006 · Cited by 15
A mathematical analysis of rebound in a target-mediated drug disposition model: I.Without feedback
Aston, P. J., Derks, G., Agoram, B. M., & van der Graaf, P. H. (2013) · Journal of Mathematical Biology · doi:10.1007/s00285-013-0675-5 · Cited by 15
Vogs, C., Bandow, N., & Altenburger, R. (2013) · Environmental Toxicology and Chemistry · doi:10.1002/etc.2139 · Cited by 15
Quantitative assessment of minimal effective concentration of erythropoiesis‐stimulating agents
Yan, X., & Krzyżański, W. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.39 · Cited by 15
Krippendorff, B., Oyarzún, D. A., & Huisinga, W. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9243-7 · Cited by 15
Thai, H., Veyrat‐Follet, C., Mentré, F., & Comets, E. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2182-1 · Cited by 14
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.